We are live on ! Find out more
SOLV icon

Solventum

87.45 USD
-0.20
0.23%
At close Updated Sep 11, 4:00 PM EDT
Pre-market
After hours
88.03
+0.58
0.66%
1 day
-0.23%
5 days
-4.32%
1 month
3.98%
3 months
10.39%
6 months
29.33%
Year to date
10.67%
1 year
18.51%
5 years
9.31%
10 years
9.31%
 

About: In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.

Employees: 20,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 64%
Neutral 28%
Negative 8%
Neutral
Seeking Alpha
4 days ago
Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Positive
Zacks Investment Research
9 days ago
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Solventum (SOLV) reported earnings 30 days ago. What's next for the stock?
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Neutral
PRNewsWire
11 days ago
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
Positive
Zacks Investment Research
11 days ago
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Positive
Zacks Investment Research
11 days ago
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
Positive
Zacks Investment Research
27 days ago
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
1 month ago
SOLV Plans Health Information Systems Business Spinoff to Drive Growth
Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.
SOLV Plans Health Information Systems Business Spinoff to Drive Growth
Positive
Zacks Investment Research
1 month ago
Here's Why Solventum (SOLV) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Solventum (SOLV) is a Strong Momentum Stock
Positive
MarketBeat
1 month ago
Solventum Q2 Earnings Call Highlights
Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.
Solventum Q2 Earnings Call Highlights
Positive
Zacks Investment Research
1 month ago
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
Price charts implemented using Lightweight Charts™